Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: The EPIC-norfolk prospective population study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 12, 2012, Pages 3058-3065

  Gurdasani, Deepti ^a,b   Sjouke, Barbara ^c   Tsimikas, Sotirios ^d   Hovingh, G Kees ^c   Luben, Robert N ^a   Wainwright, Nicholas W J ^a   Pomilla, Cristina ^a,b   Wareham, Nicholas J ^e   Khaw, Kay Tee ^a   Boekholdt, S Matthijs ^a,c   Sandhu, Manjinder S ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MRC EPIDEMIOLOGY UNIT   (United Kingdom)

Author keywords

atherosclerosis; lipoproteins; peripheral arterial disease; stroke; vascular biology

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; POPULATION RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CEREBROVASCULAR DISORDERS; COHORT STUDIES; CORONARY ARTERY DISEASE; EUROPE; FEMALE; GREAT BRITAIN; HUMANS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; STROKE;

EID: 84870059868     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.255521     Document Type: Article

References (40)

1. Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412-423
2. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)associated lipoproteinassociated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2094-2099. (Pubitemid 350287235)
3. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I. Atherogenic lipids and lipoproteins trigger CD36TLR2dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 2010;12:467-482.
4. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med. 2006;26:751-772. (Pubitemid 44716507)
5. Kamstrup PR, TybjaergHansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2339
6. Clarke R, Peden JF, Hopewell JC, et al; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518-2528.
7. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011;4:565-573.
8. Widener JM. Peripheral arterial disease and disability from NHANES 20012004 data. J Vasc Nurs. 2011;29:104-112.
9. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3:229-234. (Pubitemid 46860711)
10. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 19992000. Circulation. 2004;110:738-743. (Pubitemid 39056275)
11. Ostchega Y, PauloseRam R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 19992004. J Am Geriatr Soc. 2007;55:583-589. (Pubitemid 46496588)
12. Reid CM, Ademi Z, Nelson MR, Connor G, Chew DP, Shiel L, Smeath A, De Looze F, Steg PG, Bhatt DL, Liew D; REACH Registry Investigators. Outcomes from the REACH Registry for Australian general practice patients with or at high risk of atherothrombosis. Med J Aust. 2012;196:193-197.
13. Gornik HL, Creager MA. Contemporary management of peripheral arterial disease: I. Cardiovascular riskfactor modification. Cleve Clin J Med. 2006;73 Suppl 4:S30-S37.
14. Dieplinger B, Lingenhel A, Baumgartner N, Poelz W, Dieplinger H, Haltmayer M, Kronenberg F, Mueller T. Increased serum lipoprotein(a) concentrations and low molecular weight phenotypes of apolipoprotein(a) are associated with symptomatic peripheral arterial disease. Clin Chem. 2007;53:1298-1305. (Pubitemid 47020986)
15. Tyrrell J, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Bergin C, Feely J. Lipoprotein [Lp(a)] and peripheral vascular disease. J Intern Med. 1992;232:349-352.
16. Tseng CH. Lipoprotein(a) is an independent risk factor for peripheral arterial disease in Chinese type 2 diabetic patients in Taiwan. Diabetes Care. 2004;27:517-521.
17. Widmann MD, Sumpio BE. Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vasc Surg. 1993;7:446-451. (Pubitemid 23311654)
18. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28:354-362.
19. Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113:2623-2629. (Pubitemid 43948011)
20. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008;117:823-831. (Pubitemid 351640684)
21. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of Creactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:2481-2485. (Pubitemid 32433842)
22. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296:1363-1370. (Pubitemid 44427422)
23. Rifai N, Ma J, Sacks FM, Ridker PM, Hernandez WJ, Stampfer MJ, Marcovina SM. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem. 2004;50:1364-1371. (Pubitemid 38970643)
24. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA. 1995;274:1771-1774.
25. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPICNorfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80 suppl 1:95-103. (Pubitemid 29389613)
26. Albers JJ, Marcovina SM, Kennedy H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins AI and B. II. Evaluation and selection of candidate reference materials. Clin Chem. 1992;38:658-662.
27. Tate JR, Rifai N, Berg K, Couderc R, Dati F, Kostner GM, Sakurabayashi I, Steinmetz A. International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clin Chem. 1998;44(8 pt 1):1629-1640. (Pubitemid 28381204)
28. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB100containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011;5:673-694.
29. Tsimikas S, Mallat Z, Talmud PJ, Kastelein JJ, Wareham NJ, Sandhu MS, Miller ER, Benessiano J, Tedgui A, Witztum JL, Khaw KT, Boekholdt SM. Oxidationspecific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol. 2010;56:946-955.
30. Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and control of hypercholesterolemia among US adults: findings from the National Health and Nutrition Examination Survey, 1999 to 2000. Circulation. 2003;107:2185-2189. (Pubitemid 36547210)
31. Koschinsky ML, Marcovina SM. Structurefunction relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol. 2004;15:167-174. (Pubitemid 38453403)
32. Signorelli SS, Anzaldi M, Fiore V, Simili M, Puccia G, Libra M, Malaponte G, Neri S. Patients with unrecognized peripheral arterial disease (PAD) assessed by anklebrachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. Cytokine. 2012;59:294-298.
33. Belch JJ, Topol EJ, Agnelli G, et al Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003;163:884-892. (Pubitemid 36519734)
34. Norgren L, Hiatt WR, Dormandy JA, Hirsch AT, Jaff MR, Diehm C, Baumgartner I, Belch JJ. The next 10 years in the management of peripheral artery disease: perspectives from the 'PAD 2009' Conference. Eur J Vasc Endovasc Surg. 2010;40:375-380.
35. Rooke TW, Hirsch AT, Misra S, et al Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58:2020-2045.
36. Hopewell JC, Clarke R, Parish S, Armitage J, Lathrop M, Hager J, Collins R; Heart Protection Study Collaborative Group. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet. 2011;4:68-73.
37. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem. 2003;49:1785-1796. (Pubitemid 37340313)
38. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, Rader DJ. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol. 2008;51:1653-1662. (Pubitemid 351626406)
39. Akdim F, Tribble DL, Flaim JD, Yu R, Su J, Geary RS, Baker BF, Fuhr R, Wedel MK, Kastelein JJ. Efficacy of apolipoprotein B synthesis inhibition in subjects with mildtomoderate hyperlipidaemia. Eur Heart J. 2011;32:2650-2659.
40. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, ChasanTaber S, Tribble DL, Flaim JD, Crooke ST. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, doubleblind, placebocontrolled trial. Lancet. 2010;375:998-1006.